Key Takeaways:
-
Sales of cystic fibrosis drug Trikafta rose due to uptake in the younger pediatric population.
Vertex Pharmaceuticals Incorporated/CRISPR Therapeutics AG’s gene therapy candidate for inherited blood disorders, exagamglogene autotemcel (exa-cel), will be subject to a US advisory committee meeting, but analysts remained unconcerned amid decent Q2 revenues and other upcoming milestones.
The firm’s second-quarter revenues increased by 14% to $2.49bn, driven by the strong uptake of its cystic fibrosis treatment Trikafta/Kaftrio...








